Treatment of overactive bladder: What is on the horizon?

International Urogynecology Journal and Pelvic Floor Dysfunction

Volumn 24, Issue 1, 2013, Pages 5-13

  Murphy, Alana M ^a,b   Krlin, Ryan M ^a   Goldman, Howard B ^a  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b not available   (United States)

Author keywords

Anti muscarinic; Botulinumtoxin; Neuromodulation; Overactive bladder; adrenoreceptor agonists

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BOTULINUM TOXIN; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CANNABIS; CAPSAICIN; MIRABEGRON; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; OXYBUTYNIN; PHOSPHODIESTERASE INHIBITOR; PLACEBO; POTASSIUM CHANNEL STIMULATING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SERLOPITANT; TACHYKININ; TETRAHYDROCANNABINOLIC ACID; TOLTERODINE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; VINPOCETINE;

CONSERVATIVE TREATMENT; CONSTIPATION; DEVICE THERAPY; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; GENE THERAPY; HEADACHE; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; INCONTINENCE; NERVE STIMULATION; NEUROLOGICAL EQUIPMENT; NEUROMODULATION; NOCTURIA; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHINOPHARYNGITIS; THERAPY EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; URINARY TRACT INFECTION; URINARY URGENCY; XEROSTOMIA;

EID: 84872292143     PISSN: 09373462     EISSN: 14333023     Source Type: Journal    
DOI: 10.1007/s00192-012-1860-6     Document Type: Review

References (54)

1. Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21(1):5-26
2. Girman CJ, Jacobsen SJ, Tsukamoto T et al (1998) Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 51:428-436
3. Stewart WF, Van Rooyen JB, Cundiff GW et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327-336
4. Alhasso AA, McKinlay J, Patrick K, Stewart L (2006) Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev (4):CD003193
5. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev (4):CD003781
6. Khullar V, Cambronero J, Stroberg P et al (2011) The efficacy and tolerability of mirabegron in patients with overactive bladder - results from a European-Australian phase III trial. Eur Urol 10 [Suppl 2]:278
7. Nitti V, Herschorn S, Auerbach S, Ayers M, Lee M, Martin N (2011) The efficacy and safety of mirabegron with overactive bladder syndrome - results from a North American phase III trial. Eur Urol 10 [Suppl 2]:278
8. Nitti V, Herschorn S, Auerbach S, Martin N, Blauwet MB, Marshall T (2011) Mirabegron improves patient-reported outcomes in patients with overactive bladder syndrome - results from a North American study. J Urol 185 [Suppl 4]:e784
9. Chapple CR, Kaplan S, Mitcheson HD et al (2011) Randomized, double-blind, active-controlled phase III study to assess the long-term safety and efficacy of mirabegron in overactive bladder (OAB). Eur Urol 11 [Suppl 1]:683
10. FDA Advisory Committee Recommends Approval of Mirabegron - Investigational Overactive Bladder Treatment from Astellas. PR Newswire. 5 April 2012. Accessed 30 April 2012. < http://www.prnewswire.com/news-releases/fda- advisory-committee-recommends-approval-of-mirabegron - -investigational- overactive-bladder-treatment-from-astellas-146347915.html >
11. Moore KH, Gilpin SA, Dixon JS, Richmond DH, Sutherst JR (1992) Increase in presumptive sensory nerves of the urinary bladder in idiopathic detrusor instability. Br J Urol 70:370-372
12. Abdel-Gawad M, Dion SB, Elhilali MM (2001) Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats. J Urol 165:1739-1744
13. Quinn T, Collins C, Baird AW (2004) Mechanisms of neurokinin A- and substance P-induced contractions in rat detrusor smooth muscle in vitro. BJU Int 94:651-657
14. Lecci A, Giuliani S, Santicioli P, Maggi CA (1994) Involvement of spinal tachykinin NK1 and NK2 receptors in detrusor hyperreflexia during chemical cystitis in anaesthetized rats. Eur J Pharmacol 259:129-135
15. Doi T, Kamo I, Imai S, Okanishi S, Ikeura Y, Natsugari H (2000) Effects of TAK-637, a tachykinin receptor antagonist, on the micturition reflex in guinea pigs. Eur J Pharmacol 395:241-246
16. Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S (2010) A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. J Urol 184:616-622
17. Hougaard C, Fraser MO, Chien C et al (2009) A positive modulator of K Ca 2 and K Ca 3 channels, 4,5-dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591), inhibits bladder afferent firing in vitro and bladder overactivity in vivo. J Pharmacol Exp Ther 328:28-39
18. Kamiyama Y, Muto S, Masuda H et al (2008) Inhibitory effects of nicorandil, a K ATP channel opener and a nitric oxide donor, on overactive bladder in animal models. BJU Int 101:360-365
19. Darblade B, Behr-Roussel D, Oger S et al (2006) Effects of potassium channel modulators on human detrusor smooth muscle myogenic phasic contractile activity: potential therapeutic targets for overactive bladder. Urology 68:442-448
20. Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P (2011) Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 30:556-562
21. Denys P, Le Normand L, Ghout I et al (2012) Efficacy and Safety of Low Doses of OnabotulinumtoxinA for the Treatment of Refractory Idiopathic Overactive Bladder: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Dose-Ranging Study. Eur Urol 61:520-529
22. Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D (2011) Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev (12):CD005493
23. Dmochowski R, Chapple C, Nitti VW et al (2010) Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184:2416-2422
24. Kuo HC (2011) Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 30:1242-1248
25. Botox [package insert]. Allergan, Irvine, CA; November 2011. http://www.allergan.com/assests/pdf/botox-pi.pdf. Accessed 30 April 2012
26. Yu W, Hill WG, Apodaca G, Zeidel ML (2011) Expression and distribution of transient receptor potential (TRP) channels in bladder epithelium. Am J Physiol Renal Physiol 300:F49-F59
27. Maggi CA, Barbanti G, Santicioli P et al (1989) Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex in humans. J Urol 142:150-154
28. Juszczak K, Ziomber A, Thor PJ (2011) Effect of partial and complete blockade of vanilloid (TRPV1-6) and ankyrin (TRPA1) transient receptor potential ion channels on urinary bladder motor activity in an experimental hyperosmolar overactive bladder rat model. J Physiol Pharmacol 62:321-326
29. Miyazato M, Sugaya K, Goins WF et al (2009) Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats. Gene Ther 16:660-668
30. Tyagi V, Philips BJ, Su R et al (2009) Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 181:1932-1938
31. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J (2006) The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 17:636-641
32. Mukerji G, Yiangou Y, Agarwal SK, Anand P (2010) Increased cannabinoid receptor 1-immunoreactive nerve fibers in overactive and painful bladder disorders and their correlation with symptoms. Urology 75:1514.e15-1514.e20
33. Truss MC, Stief CG, Uckert S et al (2000) Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol 18:439-443
34. Takeda H, Yamazaki Y, Igawa Y et al (2002) Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn 21:558-565
35. Kim JC, Park EY, Seo SI, Park YH, Hwang TK (2006) Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 175:1773-1776, discussion 1776
36. Tanaka I, Nagase K, Tanase K, Aoki Y, Akino H, Yokoyama O (2010) Improvement in neurogenic detrusor overactivity by peripheral C fiber's suppression with cyclooxygenase inhibitors. J Urol 183:786-792
37. Ozdemir I, Bozkurt O, Demir O, Aslan G, Esen AA (2009) Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. Urology 74:431-435
38. Gupta SK, Sathyan G (1999) Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 39:289-296
39. Schroder A, Levin RM, Kogan BA, Das AK, Kay F, Mahashabde A (2000) Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder. Urology 56:1063-1067
40. Gittelman M, Reape K, Dasen S, Hait H (2011) A phase 2 study evaluating the safety and efficacy of two doses of a monthly oxybutynin vaginal ring in women with symptoms of overactive bladder. Int Urogynecol J 22 [Suppl 1]:S137
41. Herbison GP, Arnold EP (2009) Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev (2):CD004202
42. Spinelli M, Malaguti S, Giardiello G, Lazzeri M, Tarantola J, Van Den Hombergh U (2005) A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: description of the method and preliminary data. Neurourol Urodyn 24:305-309
43. Peters KM, Feber KM, Bennett RC (2005) Sacral versus pudendal nerve stimulation for voiding dysfunction: a prospective, single-blinded, randomized, crossover trial. Neurourol Urodyn 24:643-647
44. Peters KM, Killinger KA, Boguslawski BM, Boura JA (2010) Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn 29:1267-1271
45. Monga AB, Dmochowski R, Miller D, Altman D (2011) Prospective, randomized clinical trial of a novel, noninvasive, patient-managed neuromodulation system (PMNS) using a sacral patch for the treatment of patients with overactive bladder. Int Urogynecol J 22 (Suppl 1]:S138
46. De Seze M, Raibaut P, Gallien P et al (2011) Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn 30:306-311
47. Amarenco G, Ismael SS, Even-Schneider A et al (2003) Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder. J Urol 169:2210-2215
48. Schreiner L, dos Santos TG, Knorst MR, da Silva Filho IG (2010) Randomized trial of transcutaneous tibial nerve stimulation to treat urge urinary incontinence in older women. Int Urogynecol J 21:1065-1070
49. Wheeler JS Jr, Walter JS, Zaszczurynski PJ (1992) Bladder inhibition by penile nerve stimulation in spinal cord injury patients. J Urol 147:100-103
50. Fjorback MV, Rijkhoff N, Petersen T, Nohr M, Sinkjaer T (2006) Event driven electrical stimulation of the dorsal penile/clitoral nerve for management of neurogenic detrusor overactivity in multiple sclerosis. Neurourol Urodyn 25:349-355
51. Goldman HB, Amundsen CL, Mangel J et al (2008) Dorsal genital nerve stimulation for the treatment of overactive bladder symptoms. Neurourol Urodyn 27:499-503
52. Shafik A (1999) A study of the continence mechanism of the external urethral sphincter with identification of the voluntary urinary inhibition reflex. J Urol 162:1967-1971
53. Nissenkorn I, De Jong PR (2005) A novel surgical technique for implanting a new electrostimulation system for treating female overactive bladder: a preliminary report. BJU Int 95:1253-1258
54. Whiteside JL, Ensrud-Bowlin KM, Wang G, Watschke BP, Roberts KP (2009) Lead placement and associated nerve distribution of an implantable periurethral electrostimulator. Int Urogynecol J Pelvic Floor Dysfunct 20:325-329